UGT79B9 Antibody

Clarification of Terminology

The term "UGT79B9" likely represents a misinterpretation or typographical error. UGT enzymes are classified using a standardized nomenclature (e.g., UGT1A9, UGT2B7), where numbers and letters denote gene families, subfamilies, and isoforms. No UGT isoform or antibody with the identifier "79B9" exists in peer-reviewed literature or commercial antibody databases.

Table 1: UGT1A9 Antibody Properties

Tissue-Specific Expression

• UGT1A9 Protein Distribution:

  • Liver and Kidney: High expression confirmed via monoclonal antibody .

  • Jejunum/Ileum: Absent expression, consistent with mRNA data .

  • Interindividual Variability: 9-fold variation in UGT1A9 protein levels across 20 human livers, uncorrelated with mRNA levels (r = -0.13) .

Functional Roles in Drug Metabolism

• Key Substrates:

  • Propofol, Entacapone, Indomethacin, Mycophenolic Acid, Oxazepam .

  • SN-38 (irinotecan metabolite) and estrogen hormones (estradiol, estrone) .

• Genetic Variants:

  • UGT1A9 rs3832043: Promoter deletion reduces glucuronidation capacity, affecting SN-38 clearance .

  • UGT1A9 rs8330 CC Genotype: Alters splicing, increasing paracetamol glucuronidation and hepatotoxicity risk .

Antibody Validation and Applications

• Monoclonal Antibody :

  • Specificity: No cross-reactivity with UGT1A7, 1A8, or 1A10.

  • Applications: Western blot (WB), immunohistochemistry (IHC).

• Abcam ab180707 :

  • Suitability: WB (1/500 dilution), ICC/IF (e.g., MCF7 cells).

  • Reactivity: Human and mouse samples; predicted band size: 60 kDa.

Limitations and Future Directions

• Antibody Availability: Limited commercial options for UGT1A9; most studies rely on custom or lab-generated antibodies .

• Functional Studies: Isoform-specific antibodies remain critical for distinguishing UGT1A9 activity from homologous enzymes (e.g., UGT1A1, 1A3) .